Senior Director, Benefit-Risk / Epidemiology
Janssen Pharmaceuticals
Titusville, United States
Bennett Levitan, MD-PhD is Senior Director, Benefit-risk Assessment, Department of Epidemiology at Janssen R&D, Pharmaceutical Companies of Johnson & Johnson. He introduced state of the art patient-focused benefit-risk assessment to Johnson & Johnson and his group has led numerous clinical teams in preparation of benefit-risk assessments and patient preference studies for regulatory submissions and health authority advisory meetings. He has co-led cross-disciplinary teams to implement processes to support growing regulatory requirements for patient-focused benefit-risk assessment both during development and post-approval. Bennett has published widely on both theoretical and pragmatic aspects in benefit-risk and patient preference studies and is a frequent speaker on these topics in national and international conferences. He co-led development of the PhRMA Benefit Risk Action Team (BRAT) Framework for drug benefit-risk assessment, the Medical Device Innovation Consortium (MDIC) Patient Centered Benefit-Risk Framework, the Clinical Trials Transformation Initiative’s financial value of patient engagement project and the Innovative Medicines Initiative (IMI) PREFER project on patient preference studies. Bennett serves on several organizations and committees that inform policy on benefit-risk methods including co-leading the Brighton Collaboration BRAVATO Benefit-Risk Working Group, MDIC’s Science of Patient Input Initiative and serving as a member of the International Academy of Health Preference Research and the PhRMA Patient-Focused Drug Development Work Group. Bennett received his B.Sc. (Electrical Engineering) from Columbia University in New York and his M.D.-Ph.D. (Bioengineering) from the University of Pennsylvania and was a postdoctoral fellow at the Santa Fe Institute.
Disclosure information not submitted.
Wednesday, August 23, 2023
2:00 PM – 6:00 PM ADT
